World Conference on Lung Cancer

Melina E. Marmarelis, MD, reports the safety and efficacy data from the phase 1 CHRYSALIS-2 trial.

Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.

An easy way to double survival for patients with lung cancer is by removing the barriers to screening.

Datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy showed promising efficacy and a manageable safety profile in advanced/metastatic non–small cell lung cancer without actionable genomic alterations.

Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.

The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.

The combination of temozolomide and nivolumab demonstrated promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.

Following treatment osimertinib, EGFR C797X mutations are now the leading mechanism of acquired resistance, outpacing MET amplification.

Amivantamab in combination with lazertinib and chemotherapy combination demonstrated encouraging responses in EGFR-mutant non–small cell lung cancer.

Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.

Atezolizumab may lead to improved overall survival when compared with the best supportive care in patients with resected non–small cell lung cancer.

David S. Hong, MD, discusses the data supporting the use of larotrectinib for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib.

Sotorasib and RMC-4630 elicited promising preliminary activity in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer.

Tepotinib achieved robust efficacy in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations, according to a primary analysis of cohort C of the phase 2 VISION trial.

Pembrolizumab plus lenvatinib demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma, according to results from the PEMMELA study.

Sotorasib plus either pembrolizumab or atezolizumab revealed promising efficacy and relatively low rates of hepatotoxicity with a lead-in dosing strategy in patients with KRAS G12C–positive non–small cell lung cancer.

A phase 1a trial of GDC-6036 showed encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer.

Comparable outcomes seen with sintilimab vs pembrolizumab in patients with treatment-naïve metastatic non–small cell lung cancer.

Unique signaling pathways and significant differentially-expressed genes was found from 4 subgroups of patients with MET exon 14 skipping non–small cell lung cancer.

Treatment with concurrent sugemalimab demonstrated prolonged progression-free survival in patients with stage III unresectable non–small cell lung cancer.

Using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders is supported by the phase 2 NADIM trial.

Sacituzumab govitecan-hziy vs single-agent docetaxel with be evaluated in the phase 3 EVOKE-01 trial of patients with metastatic non–small cell lung cancer.

Overall survival benefit was sustained with second- or third-line tislelizumab in patients with non–small cell lung cancer vs docetaxel in the final analysis of the phase 3 RATIONALE-303 trial.

Ociperlimab plus tislelizumab revealed promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer.

The phase 2 Neo-KAN study revealed neoadjuvant adagrasib alone or in combination with nivolumab may improve pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer.

First-line durvalumab in combination with tremelimumab improved overall survival vs standard-of-care chemotherapy for the treatment of patients with metastatic non–small cell lung cancer.

Tremelimumab plus durvalumab and chemotherapy displayed improvements in clinical and survival benefit in patients with PD-L1 negative metastatic non–small cell lung cancer.

Larotrectinib continued to demonstrate favorable efficacy and survival outcomes with low toxicity, according to extended follow-up for 2 trials of patients with lung cancer and NTRK fusions.

Larotrectinib was observed to be highly active and have a favorable safety profile in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.